These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 10541319)

  • 41. [The clinical study of recombinant human thrombopoietin in the treatment of chemotherapy-induced severe thrombocytopenia].
    Bai CM; Zou XY; Zhao YQ; Han SM; Shan YD;
    Zhonghua Yi Xue Za Zhi; 2004 Mar; 84(5):397-400. PubMed ID: 15061993
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cyclic immune thrombocytopenia responsive to thrombopoietic growth factor therapy.
    Rice L; Nichol JL; McMillan R; Roskos LK; Bacile M
    Am J Hematol; 2001 Nov; 68(3):210-4. PubMed ID: 11754405
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Kasabach-Merritt syndrome: a case review.
    Szlachetka DM
    Neonatal Netw; 1998 Feb; 17(1):7-15. PubMed ID: 9526357
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effect of a novel, small non-peptidyl molecule butyzamide on human thrombopoietin receptor and megakaryopoiesis.
    Nogami W; Yoshida H; Koizumi K; Yamada H; Abe K; Arimura A; Yamane N; Takahashi K; Yamane A; Oda A; Tanaka Y; Takemoto H; Ohnishi Y; Ikeda Y; Miyakawa Y
    Haematologica; 2008 Oct; 93(10):1495-504. PubMed ID: 18728031
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Effect of thrombopoietin II on exsanguine thrombocytopenia mouse death rate].
    Chen Y; Zhong L; Zhong X
    Zhonghua Zhong Liu Za Zhi; 2001 Sep; 23(5):379-81. PubMed ID: 11810766
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia.
    Schiffer CA; Miller K; Larson RA; Amrein PC; Antin JH; Zani VJ; Stone RM
    Blood; 2000 Apr; 95(8):2530-5. PubMed ID: 10753831
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Decreased prothrombotic effects of pegylated recombinant human megakaryocyte growth and development factor in thrombocytopenic state in a rat thrombosis model.
    Nishiyama U; Kuwaki T; Akahori H; Kato T; Ikeda Y; Miyazaki H
    J Thromb Haemost; 2005 Feb; 3(2):355-60. PubMed ID: 15670044
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetics, pharmacodynamics, and safety of administering pegylated recombinant megakaryocyte growth and development factor to newborn rhesus monkeys.
    Sola MC; Christensen RD; Hutson AD; Tarantal AF
    Pediatr Res; 2000 Feb; 47(2):208-14. PubMed ID: 10674348
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of murine leukemia virus infection as a model for thrombocytopenia of HIV/AIDS: mechanism of thrombocytopenia and modulation of thrombocytopenia by thrombopoietin.
    Sullivan PS; McDonald TP
    AIDS Res Hum Retroviruses; 1995 Jul; 11(7):837-42. PubMed ID: 7546911
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura.
    Nomura S; Dan K; Hotta T; Fujimura K; Ikeda Y
    Blood; 2002 Jul; 100(2):728-30. PubMed ID: 12091377
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of recombinant human megakaryocyte growth and development factor coupled with polyethylene glycol on the platelet storage lesion.
    Snyder E; Perrotta P; Rinder H; Baril L; Nichol J; Gilligan D
    Transfusion; 1999 Mar; 39(3):258-64. PubMed ID: 10204587
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Case report: Kasabach-Merritt syndrome: a review of the therapeutic options and a case report of successful treatment with radiotherapy and interferon alpha.
    Hesselmann S; Micke O; Marquardt T; Baas S; Bramswig JH; Harms E; Willich N
    Br J Radiol; 2002 Feb; 75(890):180-4. PubMed ID: 11893644
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetic analysis of pegylated megakaryocyte growth and development factor in humans.
    De Boer RH; Roskos LK; Cheung E; Fox S; Basser RL; Marty J; Begley CG; Cebon J
    Growth Factors; 2000; 18(3):215-26. PubMed ID: 11334057
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reactivity of platelets from healthy individuals and from patients with hematologic diseases following incubation with pegylated recombinant human megakaryocyte growth and development factor in vitro.
    Matzdorff AC; Kemkes-Matthes B; Pralle H
    Haemostasis; 1998; 28(1):37-44. PubMed ID: 9885369
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comprehensive therapy for hemangioma presenting with Kasabach-Merritt syndrome in the maxillofacial region.
    Su L; Wang D; Fan X
    J Oral Maxillofac Surg; 2015 Jan; 73(1):92-8. PubMed ID: 25511959
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of pegylated recombinant human megakaryocyte growth and development factor on 5-fluorouracil-induced thrombocytopenia in balloon-injured rats.
    Harada K; Tazunoki Y; Ide Y; Takeuchi A; Kawahara J; Suzuki T
    J Pharm Pharmacol; 2000 Mar; 52(3):321-5. PubMed ID: 10757421
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Update on thrombopoietin in preclinical and clinical trials.
    Miyazaki H
    Curr Opin Hematol; 1998 May; 5(3):197-202. PubMed ID: 9664160
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Therapeutic potential of thrombopoietin].
    Geissler K
    Wien Klin Wochenschr; 2000 Oct; 112(19):829-34. PubMed ID: 11098533
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Successful treatment of Kasabach-Merritt syndrome with transarterial embolization and corticosteroids.
    Zhou SY; Li HB; Mao YM; Liu PY; Zhang J
    J Pediatr Surg; 2013 Mar; 48(3):673-6. PubMed ID: 23480932
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluating the safety and efficacy of recombinant human thrombopoietin among severe sepsis patients with thrombocytopenia: study protocol for a randomized controlled trial.
    Wu Q; Ren J; Wang G; Gu G; Hu D; Liu S; Li G; Chen J; Li R; Hong Z; Ren H; Wu X; Li Y; Yao M; Zhao Y; Li J
    Trials; 2015 May; 16():220. PubMed ID: 25986785
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.